Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 12/20 | 0.73 |
| ▸ | SRD5A2 | P31213 | 7/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | HSD3B1 | P14060 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | THPO | P40225 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL790854 | 1.00 | SRD5A1 (0.73) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL14295225 | 1.00 | SRD5A1 (0.73) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL790855 | 1.00 | SRD5A1 (0.73) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL13970874 | 1.00 | SRD5A1 (0.73) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL14355654 | 1.00 | SRD5A1 (0.73) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL13950489 | 1.00 | SRD5A1 (0.73) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL13403338 | 1.00 | SRD5A1 (0.73) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL24503471 | 0.88 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL790006 | 0.88 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL14477868 | 0.88 | SRD5A1 (0.74) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5138063-A | Testosterone reductase inhibitors | MERCK & CO., INC. (US) | 1992-08-11 | — | — | US | claimed |
| EP-0271219-A1 | Topical pharmaceutical composition containing 17-beta-methoxycarbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one | MERCK & CO. INC. (US) | 1988-06-15 | — | — | EP | claimed |
| JP-1093600-A | — | — | None | — | — | JP | disclosed |
| JP-4288096-A | — | — | None | — | — | JP | disclosed |
| CN-114910567-A | Method for detecting genotoxic impurities in finasteride and application thereof | 株洲千金药业股份有限公司 | 2022-08-16 | — | — | CN | disclosed |
| WO-2012035553-A1 | PROCESS FOR PREPARING ANDROSTENONE DERIVATIVES | IND-SWIFT LABORATORIES LIMITED (IN) | 2012-03-22 | — | — | WO | disclosed |
| US-7872135-B2 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2011-01-18 | — | — | US | disclosed |
| EP-1437361-B1 | METHOD OF PRODUCING 17BETA-(SUBSTITUTED)-3-OXO-DELTA 1,2-4-AZASTEROIDS | RAGACTIVES SL (ES) | 2007-10-31 | — | — | EP | disclosed |
| US-7057045-B2 | Process for obtaining 17β-(substituted)-3-oxo-Δ1,2-4-azasteroids and intermediates | RAGACTIVES, S.L. (ES) | 2006-06-06 | — | — | US | disclosed |
| US-20060100434-A1 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2006-05-11 | — | — | US | disclosed |
| US-20040254209-A1 | Process for obtaining 17beta-(substituted)-3-oxo-delta 1,2-4-azasteroids and intermediates | RAGACTIVES, S.L. | 2004-12-16 | — | — | US | disclosed |
| EP-0155096-B1 | 17 BETA-SUBSTITUTED-4-AZA-5-ALPHA-ANDROSTENONES AND THEIR USE AS 5-ALPHA-REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1989-10-04 | — | — | EP | disclosed |
| EP-0314199-A1 | 17 Beta-substituted-4-aza-5 alpha-androstenones and their use as 5 alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1989-05-03 | — | — | EP | disclosed |
| JP-H0193600-A | 17BETA-ACYL-4-AZA-5ALPHA-ANDROST-1-EN-3-ONE AS INHIBITOR OF 5ALPHA-REDUCTASE | MERCK & CO INC | 1989-04-12 | — | — | JP | disclosed |
| EP-0298652-A2 | Dehydrogenation process and intermediates | MERCK & CO. INC. (US) | 1989-01-11 | — | — | EP | disclosed |
| EP-0285383-A2 | Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0285382-A2 | Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| US-4760071-A | Enzyme inhibitor | MERCK & CO., INC. (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0271219-A1 | Topical pharmaceutical composition containing 17-beta-methoxycarbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one | MERCK & CO. INC. (US) | 1988-06-15 | — | — | EP | disclosed |
| EP-0155096-A2 | 17 Beta-Substituted-4-aza-5-alpha-androstenones and their use as 5-alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1985-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254209-A1 | Process for obtaining 17beta-(substituted)-3-oxo-delta 1,2-4-azasteroids and intermediates | SRD5A2, HSD3B1, HSD3B2 | SRD5A1 4/4885SRD5A2 1/4885LMNA 3997/4885 |
| US-20060100434-A1 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | NR3C2, NR5A1, CYP11B1 | SRD5A1 14/4885SRD5A2 7/4885LMNA 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.